Principal Investigator: Elan Pharmaceuticals Clinical Trial [ Bio ]
Site Leader: Paul Rosenberg, M.D.
The goal of this study is to determine if treatment with a vaccine (Bapineuzimab) slows the progression of cognitive decline in patients with Alzheimer’s disease (AD). Mild-to-moderately impaired patients with AD who are between the ages of 50-90 are eligible. Some of the patients will get the actual medication and some will get a placebo (a substance with no active ingredient). The study involves both clinic visits and telephone calls over a total of 18 months. The treatment involves 6 intravenous infusions over 12 months. Biological specimens and MRI scans will be taken. The presumed mechanism of action is to reduce the amount of amyloid in the brain through development of an immune response. Enrollment in the study is ongoing.
For more information regarding this study, please call 410-550-9027.
|
